CINCINNATI--(BUSINESS WIRE)--Apr. 5, 2019--
Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company
focused on developing compounds that activate Tie2 to treat ocular
diseases and diabetic complications, today announced that Chief
Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 18th
Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at
11:20 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a
corporate overview and business update.
The presentation will be webcast live and may be accessed by visiting
Aerpio's website at http://ir.aerpio.com/.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class compounds that activate Tie2 to treat ocular
diseases and complications of diabetes. Tie2 is an important regulator
of vascular stability and its down-regulation is found in patients with
diabetes and other conditions. Down-regulation is caused by activation
of two inhibitors of Tie2, VE-PTP and Ang-2. The Company’s lead
compound, AKB-9778, is being investigated for its potential utility in
treating diabetic nephropathy and an eyedrop formulation is in
development as a potential treatment for open-angle glaucoma. For more
information, please visit www.aerpio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190405005373/en/
Source: Aerpio Pharmaceuticals, Inc.
Investor & Media:
McClellan, on behalf of Aerpio Pharmaceuticals, Inc.
Steinberg / Robert Flamm, Ph.D.